{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:30:08Z","timestamp":1790515808946,"version":"4.1.0"},"reference-count":72,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,8,29]],"date-time":"2007-08-29T00:00:00Z","timestamp":1188345600000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2007,8]]},"abstract":"<jats:p><jats:bold><jats:sc>Abstract<\/jats:sc>:\u2002<\/jats:bold>  <jats:bold>The development of autoimmune diseases may be influenced by hormonal, immunomodulatory, and metabolic pathways. Prolactin (PRL), ferritin, vitamin D, and the tumor marker tissue polypeptide antigen (TPA) were measured in autoimmune diseases: systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), polymyositis (PM), dermatomyositis (DM), multiple sclerosis (MS), autoimmune thyroid diseases, and antiphospholipid syndrome. Hyperprolactinemia (HPRL) was detected in 24% of PM patients, in 21% of SLE patients, in 6.7% of MS patients, 6% of RA patients, and in 3% of SSc patients. Hyperferritinemia was detected in 23% of SLE patients, 15% of DM patients, 8% of MS patients, and 4% of RA patients. The patients had relatively low levels of 25 OH Vitamin D: the average results (mean \u00b1 SD) were between 9.3 \u00b1 4.4 to 13.7 \u00b1 7.1 ng\/mL in the different diseases, while the 25 OH Vitamin D concentrations less than 20 ng\/mL are regarded as deficient. TPA levels were in the same range of the controls, elevated only in SLE. HPRL, hyperferritinemia, hypovitaminosis D, and TPA levels did not correlate with SLE activity elevated levels of rheumatoid factor or anti\u2010CCP antibodies in RA. HPRL, hyperferritinemia, and hypovitaminosis D have different immunological implications in the pathogenesis of the autoimmune diseases. Preventive treatment with vitamin D or therapy for HPRL with dopamine agonists, may be considered in certain cases. Hyperferritinemia may be used as an acute\u2010phase reactant marker in autoimmune diseases mainly SLE. TPA may be used to indicate the tendency for malignancies.<\/jats:bold> <\/jats:p>","DOI":"10.1196\/annals.1398.044","type":"journal-article","created":{"date-parts":[[2007,9,4]],"date-time":"2007-09-04T05:08:39Z","timestamp":1188882519000},"page":"385-400","source":"Crossref","is-referenced-by-count":206,"title":["Novel Biomarkers in Autoimmune Diseases"],"prefix":"10.1111","volume":"1109","author":[{"given":"HEDI","family":"ORBACH","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GISELE","family":"ZANDMAN\u2010GODDARD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HOWARD","family":"AMITAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VIVIAN","family":"BARAK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZOLTAN","family":"SZEKANECZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GABRIELLA","family":"SZUCS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KATALIN","family":"DANKO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ENDRE","family":"NAGY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TUNDE","family":"CSEPANY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOZELIO F.","family":"CARVALHO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDREA","family":"DORIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YEHUDA","family":"SHOENFELD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,29]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2000.80.4.1523"},{"key":"e_1_2_5_3_2","first-page":"575","article-title":"Diagnosis and management of hyperprolactinemia","volume":"169","author":"Serri O.","year":"2003","journal-title":"CMAJ"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb07629.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2005.05.014"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-16-3-354"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cccn.2005.02.001","article-title":"Ferritin in atherosclerosis","volume":"357","author":"You S.A.","journal-title":"Clin. Chim. Acta"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3505"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00018-005-5285-y","article-title":"Cellular regulation and molecular interactions of the ferritins","volume":"63","author":"Hintze K.J.","journal-title":"Cell. Mol. Life Sci."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3521"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00202.x"},{"key":"e_1_2_5_12_2","first-page":"205","article-title":"Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors","volume":"31","author":"Moll R.","year":"1998","journal-title":"Subcell. Biochem."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2004.05.009"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1155\/1998\/93086"},{"key":"e_1_2_5_15_2","first-page":"583","article-title":"Influence of prolactin on the differentiation of mouse B\u2010lymphoid precursors","volume":"10","author":"Morales M.","year":"1999","journal-title":"Cell Growth Differ."},{"key":"e_1_2_5_16_2","first-page":"39","article-title":"Elevation of serum ferritin levels as a marker for active systemic lupus erythematosus","volume":"15","author":"Nishiya K.","year":"1997","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_5_17_2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V83.3.737.737","article-title":"H and L\u2010rich ferritins suppress antibody production, but not proliferation of human B lymphocytes in vitro","volume":"83","author":"Morikawa K.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890615)63:12<2492::AID-CNCR2820631222>3.0.CO;2-7"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.153.6.1426"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3521"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00202.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10580"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.4974"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2337\/diab.41.11.1491","article-title":"1,25\u2010Dihydroxyvitamin D3 prevents insulitis in NOD mice","volume":"41","author":"Mathieu C.","year":"1992","journal-title":"Diabetes"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2000.4998"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1029"},{"key":"e_1_2_5_27_2","first-page":"689","article-title":"Comparison of cytokeratin fragment 19 (CYFRA 21\u20101), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer","volume":"31","author":"Stieber P.","year":"1993","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690230"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339600500107"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.10.005"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.046904"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655202753416876"},{"key":"e_1_2_5_33_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s001250051112","article-title":"Vitamin D supplement in early childhood and risk for type I (insulin dependent) diabetes mellitus","volume":"42","author":"The EURODIAB substudy 2 Study Group","year":"1999","journal-title":"Diabetologia"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000209423.39033.94"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200301000-00007"},{"key":"e_1_2_5_36_2","first-page":"629","article-title":"No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus","volume":"23","author":"Buskila D.","year":"1996","journal-title":"J. Rheumatol."},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei115"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120301701549688"},{"key":"e_1_2_5_39_2","first-page":"2216","article-title":"Elevated bioactive prolactin levels in systemic lupus erythematosus\u2010association with disease activity","volume":"28","author":"Pacilio M.","year":"2001","journal-title":"J. Rheumatol."},{"key":"e_1_2_5_40_2","first-page":"55","article-title":"Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power","volume":"26","author":"Blanco\u2010Favela F.","year":"1999","journal-title":"J. Rheumatol."},{"key":"e_1_2_5_41_2","first-page":"2084","article-title":"Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus","volume":"22","author":"McMurray R.W.","year":"1995","journal-title":"J. Rheumatol."},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678920334"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002960000083"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740310003712"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740310002489"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.3177\/jnsv.36.21"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.05.009"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1979.tb04969.x"},{"key":"e_1_2_5_49_2","first-page":"2535","article-title":"Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia","volume":"28","author":"Huisman A.M.","year":"2001","journal-title":"J. Rheumatol."},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02207671"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04224.x"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100670200076"},{"key":"e_1_2_5_53_2","first-page":"1662","article-title":"Prolactin deficiency in rheumatoid arthritis","volume":"18","author":"Nagy E.","year":"1991","journal-title":"J. Rheumatol."},{"key":"e_1_2_5_54_2","first-page":"28","article-title":"Hormones, pregnancy and rheumatoid arthritis","volume":"5","author":"Olsen N.J.","year":"2002","journal-title":"J. Gend. Specif. Med."},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.25482"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.2.237"},{"key":"e_1_2_5_57_2","first-page":"2284","article-title":"Treatment of rheumatoid arthritis with the dopamine agonist quinagolide","volume":"26","author":"Eijsbouts A.","year":"1999","journal-title":"J. Rheumatol."},{"key":"e_1_2_5_58_2","first-page":"423","article-title":"Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis","volume":"34","author":"Yildirim K.","year":"2004","journal-title":"Ann. Clin. Lab. Sci."},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070052"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.9.841"},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(91)90094-N"},{"key":"e_1_2_5_62_2","first-page":"216","article-title":"Serum prolactin and sex hormone concentration in patients with multiple sclerosis","volume":"5","author":"Zych\u2010Twardowska E.","year":"1999","journal-title":"Med. Sci. Monit."},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-6-19"},{"key":"e_1_2_5_64_2","doi-asserted-by":"publisher","DOI":"10.1006\/brbi.2001.0628"},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.6.1067"},{"key":"e_1_2_5_66_2","first-page":"177","article-title":"Serum prolactin level in patients with multiple sclerosis: a case control study","volume":"12","author":"Harirchian M.H.","year":"2006","journal-title":"Med. Sci. Monit."},{"key":"e_1_2_5_67_2","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1171oa"},{"key":"e_1_2_5_68_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.9.1687"},{"key":"e_1_2_5_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.23.2832"},{"key":"e_1_2_5_70_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-17904"},{"key":"e_1_2_5_71_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.44.89"},{"key":"e_1_2_5_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(91)90084-A"},{"key":"e_1_2_5_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199905000-00001"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1398.044","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1398.044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:50:11Z","timestamp":1695639011000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1398.044"}},"subtitle":["Prolactin, Ferritin, Vitamin D, and TPA Levels in Autoimmune Diseases"],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1196\/annals.1398.044"],"URL":"https:\/\/doi.org\/10.1196\/annals.1398.044","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}